Search for a clinical trial
Other search option(s)
45 Result(s)
Recruiting trial
= 
; Ongoing trial
= 
; Terminated trial = 
; Funded by an IRDiRC member = 
; Member of a ERN = 
National clinical trial(s)
GERMANY
Hessen
MARBURG
SONNET: Phase II, Multicentre, Open Label Study to Evaluate the Efficacy of the Combination of Lanreotide Autogel 120mg and Temozolomide in Patients With Progressive Gastro-entero-pancreatic Neuroendocrine Tumours (GEP-NET) G1/G2 - A Pilot-Study
Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg
Klinik für Visceral- Thorax- und Gefäßchirurgie
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Efficacy and safety of lanreotide Autogel® 120 mg administered every 14 days in well differentiated, metastatic or locally advanced, unresectable pancreatic or midgut neuroendocrine tumours having progressed radiologically while previously treated with lanreotide Autogel® 120 mg administered every 28 days (phase II)- BE
Cliniques universitaires Saint-Luc - UCLouvain
Oncologie digestive
FRANCE
ILE-DE-FRANCE
VILLEJUIF
OCCLURANDOM : Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium-Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II
CLCC Institut Gustave Roussy
Cancers endocriniens - Surrénales et Tumeurs neuro-endocrines
FRANCE
ILE-DE-FRANCE
VILLEJUIF
Efficacy and safety of lanreotide Autogel® 120 mg administered every 14 days in well differentiated, metastatic or locally advanced, unresectable pancreatic or midgut neuroendocrine tumours having progressed radiologically while previously treated with lanreotide Autogel® 120 mg administered every 28 days (Phase II) - FR
CLCC Institut Gustave Roussy
Cancers endocriniens - Surrénales et Tumeurs neuro-endocrines
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
Efficacy and safety of lanreotide Autogel® 120 mg administered every 14 days in well differentiated, metastatic or locally advanced, unresectable pancreatic or midgut neuroendocrine tumours having progressed radiologically while previously treated with lanreotide Autogel® 120 mg administered every 28 days (phase II)- DE-
Institution: Information not provided - DE
GERMANY
Berlin
BERLIN
CSOM230D2203: An open label, multicentre, single arm phase II study of Pasireotide LAR in patients with Rare Tumors of Neuroendocrine Origin - DE
Charité - Universitätsmedizin Berlin (CCM)
Medizinische Klinik für Endokrinologie, Diabetes und Ernährungsmedizin
GERMANY
Sachsen-Anhalt
HALLE (SAALE)
RamuNet: A multicenter single-arm pilot study of ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors
Universitätsklinikum Halle (Saale)
Universitätsklinik und Poliklinik für Innere Medizin I
IRELAND
County Dublin
DUBLIN
Efficacy and safety of lanreotide Autogel® 120 mg administered every 14 days in well differentiated, metastatic or locally advanced, unresectable pancreatic or midgut neuroendocrine tumours having progressed radiologically while previously treated with lanreotide Autogel® 120 mg administered every 28 days - IE
St. Vincent's University Hospital
Endocrinology Department
ITALY
LOMBARDIA
MILANO
A Phase II Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in Gastroenteropancreatic (GEP) and Thoracic Neuroendocrine Tumor (NET): The LOLA Trial
Fondazione IRCCS Istituto Nazionale dei Tumori
S.S. Oncologia Medica Gastroenterologica
SPAIN
Cataluña
L'HOSPITALET DE LLOBREGAT
SEQTOR: Randomized open label study to compare the efficacy and safety of everolimus followed by chemotherapy with STZ-5FU upon progression or the reverse sequence, chemotherapy with STZ-5FU followed by everolimus upon progression, in advanced progressive pNETs (Phase III) - ES
ICO Hospitalet - Hospital Duran i Reynals
Servicio de Oncología Médica
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
KEYNOTE-158: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors - ES
Institution: Information not provided - ES
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
Randomized Phase II Study of Everolimus Alone Versus Everolimus Plus Bevacizumab in Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors
Institution: Information not provided - US
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
COMPETE: A Prospective, Randomised, Controlled, Open-label, Multicentre Phase III Study to Evaluate Efficacy and Safety of Peptide Receptor Radionuclide Therapy With 177Lu-Edotreotide Compared to Targeted Molecular Therapy With Everolimus in Patients With Inoperable, Progressive, Somatostatin Receptor-positive, Neuroendocrine Tumours of Gastroenteric or Pancreatic Origin - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
An Open Label Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), That Have Progressed on Prior Treatment - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
An Open-Label, Multicohort, Phase II Study of Atezolizumab in Advanced Solid Tumors (Phase 2) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
WIEN
An International, Multicenter, Open-label Study to Evaluate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor-positive Neuroendocrine Tumors (NETs) - AT
Medizinische Universität Wien
Klinische Abteilung für Nuklearmedizin
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
SCIROCCO: Sandostatin (Octreotide LAR) may lead to clinical improvement through receptor occupation optimisation. A prospective interventional trial of patients with neuro-endocrine tumors with carcinoid syndrome receiving octreotide LAR
Cliniques universitaires Saint-Luc - UCLouvain
Cliniques Universitaires Saint-Luc
FRANCE
ILE-DE-FRANCE
CLICHY
TERAVECT : A Randomized Phase III of Adjuvant Targeted Radionuclide Therapy With In111-Pentetreotide in Patients With Digestive Neuroendocrine Tumors After Complete Surgical Resection of Liver Metastases
CHU Paris Nord-Val de Seine - Hôpital Beaujon
Service de Pancréato-gastroentérologie
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
COMPETE: Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients -GB
Institution: Information not provided - DE
GERMANY
Berlin
BERLIN
CLARINET: Phase III, randomised, double-blind, stratified comparative, placebo controlled, parallel group, multi-centre study to assess the effect of deep subcutaneous injections of Lanreotide Autogel 120mg administered every 28 days on tumour progression free survival in patients with non-functioning Entero-pancreatic Endocrine Tumour
Charité - Universitätsmedizin Berlin (CVK)
Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie (CVK)
GERMANY
Thüringen
BAD BERKA
COMPETE: Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients -DE-
Zentralklinik Bad Berka GmbH
Zentrum für Neuroendokrine Tumoren Bad Berka
ITALY
EMILIA ROMAGNA
MELDOLA
LUCAS - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors: a Randomized Phase II Study
IRST - Istituto Scientifico Romagnolo per lo studio e la cura dei Tumori
UO Medicina Nucleare
SPAIN
Cataluña
BARCELONA
DUNE: A phase II study of durvalumab (MEDI4736) plus tremelimumab for the treatment of patients with advanced neuroendocrine neoplasms of gastroenteropancreatic or lung origin - ES
Hospital Universitari Vall d'Hebron
Servicio de Oncología Médica
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
COMPETE: A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with [...], neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET) - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
NETTER-2: This is a multicenter, stratified, randomized, open-label comparator-controlled, Phase III study in patients with somatostatin receptor positive, well-differentiated G2 and G3, advanced GEP NETs, diagnosed within 6 months prior to screening, comparing treatment with Lutathera [...] plus octreotide long-acting [...] - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
COMPOSE: A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate [...] Lutetium (177Lu) Edotreotide [...] in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin - ES
Institution: Information not provided - ES
SPAIN
Madrid
MADRID
NICE-NEC: A phase II study of Platinum-doublet chemotherapy in combination with nivolumab as first-line treatment, in subjects with unresectable, locally advanced or metastatic G3 Neuroendocrine Neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or of unknown (UK) origin - ES
Hospital Universitario 12 de Octubre
Servicio de Oncología Médica
SWITZERLAND
Suisse Alémanique
BASEL
An International, Multicenter, Open-label Study to Evaluate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor-positive Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs) - CH
Universitätsspital Basel
Tumorzentrum
SWITZERLAND
Suisse Romande
ADDRESS: NOT PROVIDED - CH
COMPETE: Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients - CH
Institution: Information not provided - CH
UNITED KINGDOM
Greater London
LONDON
An International, Multicenter, Open-label Study to Evaluate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor-positive Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs)GB
Royal Free Hospital
Department of Oncology
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
NETTER-1: A Multicentre, Stratified, Open, Randomized, Comparator-controlled, Parallel-group Phase III Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours - AT
Institution: Information not provided - AT
FRANCE
BOURGOGNE-FRANCHE-COMTE
BESANÇON
EPICentro : Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors (Phase II)
CHU de Besançon - Hôpital Jean Minjoz
Service d'oncologie médicale
FRANCE
ILE-DE-FRANCE
VILLEJUIF
AcSé : Secured Access to Pembrolizumab for Adult Patients With Selected Rare Cancer Types (Phase II)
CLCC Institut Gustave Roussy
Département d'Innovation Thérapeutique et d'Essais Précoces
GERMANY
Bayern
ERLANGEN
EVINEC: Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study - DE
Internistisches Zentrum des Universitätsklinikums Erlangen
Medizinische Klinik 1 - Gastroenterologie, Pneumologie und Endokrinologie
ITALY
EMILIA ROMAGNA
MELDOLA
A Phase II Study on Adjuvant Vaccination With Dendritic Cells Loaded With Autologous Tumor Homogenate in Resected Stage IV Rare Cancers: Head&Neck (H&N), Neuroendocrine Tumors (NET) and Soft Tissue Sarcoma (STS)
IRST - Istituto Scientifico Romagnolo per lo studio e la cura dei Tumori
Dipartimento di Oncologia ed ematologia clinica e sperimentale
ITALY
EMILIA ROMAGNA
MELDOLA
LUTHREE - Randomized Phase II Trial in sstr2 Positive Tumors to Optimize the Interval Between Cycles of PRRT With 177lu-dotatate Study
IRST - Istituto Scientifico Romagnolo per lo studio e la cura dei Tumori
UO Medicina Nucleare
ITALY
PUGLIA
SAN GIOVANNI ROTONDO
Bevacizumab in association with slow-relapsing Octreotide and Capecitabine in patients with well-differentiated neuroendocrine neoplasia and in advanced phase (Phase II)
Fondazione IRCCS Ospedale Casa Sollievo della Sofferenza
U.O. di Oncologia
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
An open label, multicenter pasireotide roll over protocol for patients who have completed a previous Novartis sponsored pasireotide study and are judged by the investigator to benefit from continued pasireotide treatment - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
An Open-Label Phase 2 Study of Surufatinib in Patients with Neuroendocrine Tumours in Europe - ES
Institution: Information not provided - ES
NETHERLANDS
Noord-Holland
AMSTERDAM
The Drug Rediscovery Protocol (DRUP trial): A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile (Phase II)
Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis
Afdeling Maag-Darm-Leveroncologie
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STEP: Sorafenib Long Term Extension Program - BE
Cliniques universitaires Saint-Luc - UCLouvain
Pneumologie_Oncologie thoracique
ITALY
LAZIO
ROMA
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias or Solid Tumors in Pediatric Participants - IT
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO
U.O. di Oncoematologia
Multinational clinical trial(s)
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
CLARINET FORTE: Efficacy and safety of lanreotide Autogel® 120 mg administered every 14 days in well differentiated, metastatic or locally advanced, unresectable pancreatic or midgut neuroendocrine tumours having progressed radiologically while previously treated with lanreotide Autogel® 120 mg administered every 28 days
Institution: Information not provided - FR
UNITED STATES
New Jersey
RAHWAY
KEYNOTE 158: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors
Merck, Sharp & Dohme Corp.
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE